Position in NVS
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$766,517
+$78,073 QoQ
Shares Held
4,891
+8.5% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#714
of 1,603 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026XPONANCE LLC holds $673,665,379 across 15 Drug Manufacturers - General names. NVS ranks #10 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
222,559 | $266,943,963 | |
| 2 | JNJ |
Johnson & Johnson
|
466,851 | $118,566,148 | |
| 3 | ABBV |
AbbVie Inc.
|
350,912 | $88,303,495 | |
| 4 | MRK |
Merck & Co., Inc.
|
473,483 | $60,842,565 | |
| 5 | AMGN |
Amgen Inc
|
133,818 | $48,458,174 | |
| 6 | GILD |
Gilead Sciences, Inc.
|
238,168 | $30,090,145 | |
| 7 | PFE |
Pfizer Inc
|
1,108,420 | $26,690,753 | |
| 8 | BMY |
Bristol Myers Squibb Co
|
444,025 | $25,584,720 |
All Filings in NVS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $766,517 | 4,891 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $688,444 | 4,507 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $488,887 | 3,546 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $407,674 | 3,179 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $335,318 | 2,771 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $303,783 | 2,725 | Shares | Sole | 2025-05-01 | |
| 2024-12-31 | $253,006 | 2,600 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $283,984 | 2,469 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $233,360 | 2,192 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||